About Premaitha Health PLC
Premaitha Health PLC is engaged in molecular diagnostics business for research into, and the development and commercialization of gene analysis techniques for pre-natal screening and other clinical applications in the early detection, monitoring and treatment of disease. The Company's product, the IONA test is a non-invasive in vitro diagnostic product for prenatal screening enabling clinical laboratories to offer a regulated non-invasive prenatal test in-house. The IONA test estimates the risk of a fetus having Down's syndrome or other serious genetic diseases. The risks that fetus may be affected with include Trisomy 21 (Down's syndrome), Trisomy 18 (Edwards' syndrome), Trisomy 13 (Patau's syndrome) and Fetal sex determination optional. The analysis is performed on cell-free placental deoxyribonucleic acid (DNA) from a maternal blood sample, with test results available in three days turnaround time. The Company operates in the United Kingdom and Rest of the World.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Exchange: LON
- Symbol: NIPT
- Previous Close: $0.14
- 50 Day Moving Average: $8.81
- 200 Day Moving Average: $9.24
- 52-Week Range: £2,281,630 - GBX 6.50
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Market Cap: $26.24M
- Outstanding Shares: 228,163,000
Consensus Ratings for Premaitha Health PLC (LON:NIPT) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||1 Buy Rating|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||GBX 21|
Analysts' Ratings History for Premaitha Health PLC (LON:NIPT)
(Data available from 2/26/2015 forward)
|2/26/2017||FinnCap||Reiterated Rating||Corporate||GBX 18|
|7/4/2016||Panmure Gordon||Reiterated Rating||Buy||GBX 24|
Earnings History for Premaitha Health PLC (LON:NIPT)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Premaitha Health PLC (LON:NIPT)
Current Year EPS Consensus Estimate: $-2.34 EPS
Dividend History for Premaitha Health PLC (LON:NIPT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Premaitha Health PLC (LON:NIPT)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/17/2015||Hextall,Barry Kenneth||Insider||Buy||180,736||GBX 18||£32,532.48|
Latest Headlines for Premaitha Health PLC (LON:NIPT)
What is Premaitha Health PLC's stock symbol?
Premaitha Health PLC trades on the London Stock Exchange (LON) under the ticker symbol "NIPT."
Where is Premaitha Health PLC's stock going? Where will Premaitha Health PLC's stock price be in 2017?
1 analysts have issued 12 month price objectives for Premaitha Health PLC's shares. Their forecasts range from GBX 18 to GBX 24. On average, they anticipate Premaitha Health PLC's stock price to reach GBX 21 in the next twelve months.
How do I buy Premaitha Health PLC stock?
Shares of Premaitha Health PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
How much does a share of Premaitha Health PLC stock cost?
One share of Premaitha Health PLC stock can currently be purchased for approximately GBX 11.50.